Mankind Pharma
Ticker > Company >

Mankind Pharma share price

Mankind Pharma Ltd.

NSE: MANKIND BSE: 543904 SECTOR: Pharmaceuticals & Drugs  2.03 L   505   151

2564.75
+20.70 (0.81%)
BSE: Today, 10:37 AM

Price Summary

Today's High

₹ 2574

Today's Low

₹ 2516.15

52 Week High

₹ 2670

52 Week Low

₹ 1909.9

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 105923.14 Cr.

Enterprise Value

₹ 111069.62 Cr.

No. of Shares

41.3 Cr.

P/E

51.99

P/B

6.48

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  395.87

CASH

₹ 159.22 Cr.

DEBT

₹ 5305.7 Cr.

Promoter Holding

72.63 %

EPS (TTM)

₹  49.34

Sales Growth

9.61%

ROE

13.31 %

ROCE

13.32%

Profit Growth

18.14 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Mankind Pharma Ltd.

Rivotril Moxikind Mahacef Zenflox Cefakind Telmikind Amlokind Zolahart Overzyme Pantakind Ranidom Asthakind Combihale Nurokind Nurokind Plus Nurokind Gold Health OK Dynaglipt Glimestar Glykind-M Voglistar Unwanted-21 Days Prega News AcneStar Ring-Out Daffy Codistar Clonafit Manforce Epic Health OK Unwanted-72 AcneStar Kabz End Ring-Out Safe Kind Kaloree-1 Heal-O-Kind Calsimust Gel Multistar Liquid Calcimust Strong Liquid Nurokind-Plus Vet Injection Enerdyna Liquid Totavit Strong Powder Ceftiforce Injection Enrostrong

Index Presence

The company is present in 31Indices.

NIFTYMIDCAP

NIFTY Midcap 100
62300.6
  -687 (-1.09069086613873%)

NFTMIDSMLHEALTH

Nifty MidSmall Healthcare
50704.8
  -872.199999999997 (-1.69106384628807%)

NIFTYPHARMA

Nifty Pharma
25752.25
  -340.599999999999 (-1.30533843562508%)

NIFTY500

Nifty 500
23145.05
  -207.100000000002 (-0.886856242358847%)

NIFTYMIDCAP150

Nifty Midcap 150
22925.55
  -244.950000000001 (-1.05716320321099%)

NFT500HEALTH

Nifty500 Healthcare Index
21155.7
  -265.899999999998 (-1.24127049333382%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
21082.6
  -243.900000000001 (-1.14364757461375%)

NFTMIDSML40050:50

Nifty MidSmallcap400 50:50
20533.6
  -245.950000000001 (-1.18361562209%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
18318.85
  -193.450000000001 (-1.04498090458777%)

MIDCAP50

Nifty Midcap 50
17884.15
  -207.049999999999 (-1.14447908375342%)

NIFTYLGEMID250

NIFTY LargeMidcap 250
16582.05
  -152.700000000001 (-0.912472549634746%)

NY500MUL50:30:20

Nifty500 Multicap India Manufacturing 50:30:20
16402.85
  -139.400000000001 (-0.842690685970782%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
16391.25
  -161.5 (-0.975668695533971%)

NIFTYHEALTH

Nifty Healthcare Index
16350.95
  -196.549999999999 (-1.18779271793322%)

NFT500EQUAL

Nifty 500 Equal Weight
14809.95
  -161.949999999999 (-1.08169303829173%)

NIFTY200

Nifty 200
13894.15
  -116.6 (-0.832218118230643%)

NIFTYTOTALMCAP

NIFTY Total Market
13055.7
  -118.549999999999 (-0.899861472190067%)

NIFTYFPI150

Nifty India FPI 150
1554
  -12.95 (-0.826446280991744%)

BSE HC

Bse Healthcare
49821.23
  -643.18 (-1.27452198489986%)

BSE500

Bse 500
36196.43
  -321.849999999999 (-0.881339427815331%)

MID150

Bse 150 MidCap Index
16881.1
  -179.550000000003 (-1.05242180104511%)

200EQW

BSE 200 Equal Weight
13623.46
  -115.140000000001 (-0.838076659921694%)

MSL400

Bse 400 MidSmallCap Index
12580.64
  -148.75 (-1.16855560242871%)

BSE200

Bse 200
11252.63
  -92.6500000000015 (-0.816639166243593%)

BSE1000

Bse 1000
10827.76
  -96.9799999999996 (-0.887709913462464%)

LMI250

Bse 250 LargeMidCap Index
10715.72
  -88.5900000000001 (-0.819950556768545%)

S&P LARGEMIDCAP

Bse LargeMidCap
10319.66
  72.75 (0.709970127579918%)

ALLCAP

Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

LRGCAP

Bse LargeCap
9608.2
  -112.73 (-1.15966270716896%)

SHA500

Bse 500 Shariah
9113.66
  125.5 (1.39628133010539%)

BSESELECTIPO

BSE Select IPO Index
4603.55
  -59.8199999999997 (-1.28276332351925%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year9.61%
3 Year8.64%
5 Year13.54%

Profit Growth

1 Year14.09%
3 Year17.74%
5 Year13.45%

ROE%

1 Year13.31%
3 Year16%
5 Year18.02%

ROCE %

1 Year13.32%
3 Year18.21%
5 Year21.54%

Debt/Equity

0.3245

Price to Cash Flow

38.49

Interest Cover Ratio

5.1156

CFO/PAT (5 Yr. Avg.)

1.15735803802946

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2026 72.63 0.00
Mar 2026 72.66 0.00
Dec 2025 72.66 0.00
Sep 2025 72.67 0.00
Jun 2025 72.68 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 17.7430683979685% for the Past 3 years.
  • The Company has been maintaining an effective average operating margins of 24.5145956200102% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -14.6415 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.15735803802946.
  • The company has a high promoter holding of 72.63%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.03668727718526.

 Limitations

  • The company has shown a poor revenue growth of 8.64067543780964% for the Past 3 years.
  • Tax rate is low at 11.9844.
  • The company is trading at a high PE of 51.99.
  • The company is trading at a high EV/EBITDA of 32.2235.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Net Sales 2119.46 2541.36 2608.78 2632.68 2581.82
Total Expenditure 1777.62 1868.29 1915.59 1854.43 1662.98
Operating Profit 341.84 673.07 693.19 778.25 918.84
Other Income 219.51 64.22 77.67 56.52 126.7
Interest 165.12 146.7 147.2 138.37 125.28
Depreciation 114.78 96.93 99.03 107.69 109.43
Exceptional Items 0 0 0 -83.42 -22.82
Profit Before Tax 281.45 493.66 524.63 505.29 788.01
Tax 46.29 80.9 65.73 55.82 74.4
Profit After Tax 235.16 412.76 458.9 449.47 713.61
Adjusted EPS (Rs) 5.7 10 11.12 10.89 17.29

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Net Sales 7486.22 8127.15 8629.25 9507.41 10421.18
Total Expenditure 5647.73 6429.29 6362.36 7082.07 7334.97
Operating Profit 1838.49 1697.86 2266.89 2425.34 3086.21
Other Income 203.81 162.78 270.5 493.42 326.1
Interest 47.54 28.23 16.93 377.5 562.5
Depreciation 123.33 269.58 335.26 394.76 428.57
Exceptional Items 0 0 0 0 -106.24
Profit Before Tax 1871.44 1562.84 2185.2 2146.5 2315
Tax 482.01 314.58 412.57 421.74 277.44
Net Profit 1389.42 1248.26 1876.16 1785.99 2037.56
Adjusted EPS (Rs.) 34.68 31.16 44.25 41.8 49.36

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity and Liabilities
Share Capital 40.06 40.06 40.06 41.26 41.28
Total Reserves 6500.39 7743.85 9662.71 14281.46 16355.66
Borrowings 0 0 0 5024.7 2470.56
Other N/C liabilities 126.98 168.12 197.06 151.93 111.16
Current liabilities 2271.27 1419.09 1616.56 4958.88 5473.19
Total Liabilities 8938.7 9371.12 11516.39 24458.23 24451.85
Assets
Net Block 2921.3 3136.89 3546.28 4075.97 3925.81
Capital WIP 355.28 437.83 134.74 191.36 387.27
Intangible WIP 31.28 56.95 74.7 16.07 32.77
Investments 1657.08 2040.76 1975.85 15124.52 15472.01
Loans & Advances 146.3 148.86 142.85 182.22 409.92
Other N/C Assets 14.45 36.1 15.12 150.09 40.94
Current Assets 3813.01 3513.72 5626.85 4718 4183.13
Total Assets 8938.7 9371.12 11516.39 24458.23 24451.85
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Profit from operations 1871.44 1562.84 2325.72 2230.87 2315
Adjustment -4.16 227 164.74 472.29 731.49
Changes in Assets & Liabilities -585.61 294.21 -333.38 118.48 180.36
Tax Paid -460.22 -285.06 -421 -471.48 -474.86
Operating Cash Flow 821.44 1798.99 1736.08 2350.16 2751.99
Investing Cash Flow -1360.27 -1040.61 -1665.19 -12177.6 -388.09
Financing Cash Flow 578.63 -710.41 -4.73 9816.5 -2476.92
Net Cash Flow 39.81 47.96 66.16 -10.94 -113.02

Corporate Actions

Investors Details

PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
promoters 72.68 72.67 72.66 72.66 72.63
arjun juneja 1.98 1.98 1.98 1.98 1.97
chanakya juneja 0.94 0.94 0.94 0.94 0.94
eklavya juneja 0.94 0.94 0.94 0.94 0.94
mishka arora - 0.72 0.72 0.72 0.72
poonam juneja 2.56 2.56 2.56 2.56 2.56
prem sheetal family trust... 14.96 14.96 14.96 14.96 14.95
puja juneja 2.79 2.79 2.79 2.79 2.79
rajeev juneja 1.57 1.57 1.57 1.57 1.57
rajeev juneja family trus... 19.37 19.36 19.36 19.36 19.35
ramesh juneja 1.66 1.66 1.66 1.66 1.66
ramesh juneja family trus... 20.20 20.19 20.19 20.19 20.18
ria chopra juneja 0.31 0.31 0.31 0.31 0.31
sheetal arora 4.67 4.67 4.67 4.67 4.67
mishka arora 0.72 - - - -
PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
investors 27.32 27.33 27.34 27.34 27.37
government pension fund g... 1.63 1.68 1.65 1.53 1.29
nippon life india trustee... - - - 1.45 2.07
nps trust - a/c sbi pensi... - - - - 2.77
sbi arbitrage opportuniti... - 1.46 1.50 - 1.56
axis mutual fund trustee ... 1.17 - 1.17 1.32 -
nps trust- a/c sbi pensio... - - - 2.77 -
sbi nifty 500 index fund - - - 1.55 -
nippon life india trustee... - - 1.29 - -
nps trust a/c - lic pensi... - - 2.61 - -
axis focused fund account... - 1.30 - - -
nps trust- a/c icici prud... - 2.08 - - -
sbi life insurance co. lt... - 1.19 - - -
nps trust a/c - sbi pensi... 1.59 - - - -
sbi healthcare opportunit... 1.45 - - - -
sbi life insurance co. lt... 1.07 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2026
Annual Report 2024
Annual Report 2023

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CARE
Credit ICRA
Credit ICRA
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
Research Geojit

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY25
Concall Q4FY24
Concall Q3FY25
Concall Q3FY24
Concall Q2FY24
Concall Q1FY25
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY23
Presentation Q3FY25
Presentation Q3FY24
Presentation Q2FY24
Presentation Q1FY25
Presentation Q1FY25
Presentation Q1FY25
Presentation H1FY24

Company News

 No Latest News available for this company.Report us

Mankind Pharma Stock Price Analysis and Quick Research Report. Is Mankind Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Mankind Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Mankind Pharma has a PE ratio of 51.5788641582938 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Mankind Pharma has ROA of 8.3319% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Mankind Pharma has a Current ratio of 0.7643.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Mankind Pharma has a ROE of 13.3051%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Mankind Pharma has a Debt to Equity ratio of 0.3245 which means that the company has low proportion of debt in its capital.

  • Sales growth: Mankind Pharma has reported revenue growth of 9.6111% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Mankind Pharma for the current financial year is 29.6147845061692%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Mankind Pharma is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Mankind Pharma is Rs 49.3361. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Mankind Pharma in Ticker for free. Also, one can get the intrinsic value of Mankind Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Mankind Pharma FAQs

Q1. What is Mankind Pharma share price today?
Ans: The current share price of Mankind Pharma is Rs 2544.7.

Q2. What is the market capitalisation of Mankind Pharma?
Ans: Mankind Pharma has a market capitalisation of Rs 105095.08652166 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Mankind Pharma?
Ans: The PE ratio of Mankind Pharma is 51.5788641582938 and the P/B ratio of Mankind Pharma is 6.42813333292916, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Mankind Pharma share?
Ans: The 52-week high share price of Mankind Pharma is Rs 2689.4, and the 52-week low share price of Mankind Pharma is Rs 1909.7.

Q5. Does Mankind Pharma pay dividends?
Ans: Currently, Mankind Pharma does not pay dividends. Dividend yield of Mankind Pharma is around 0%.

Q6. What are the face value and book value of Mankind Pharma shares?
Ans: The face value of Mankind Pharma shares is Rs 1, while the book value per share of Mankind Pharma is around Rs 395.8692. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Mankind Pharma?
Ans: Mankind Pharma has a total debt of Rs 5305.7 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Mankind Pharma?
Ans: The ROE of Mankind Pharma is 13.3051% and ROCE of Mankind Pharma is 13.3156%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Mankind Pharma a good buy for the long term?
Ans: The Mankind Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Mankind Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Mankind Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Mankind Pharma’s financials?
Ans: You can review Mankind Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Mankind Pharma

Mankind Pharma Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Mankind Pharma Ltd. is a reputed pharmaceutical company that specializes in the development, production, and marketing of high-quality generic medicines. Established in XXXX, the company has since grown to become one of the leading players in the Indian pharmaceutical industry. Mankind Pharma operates with a vision to provide affordable and accessible healthcare solutions to people across the globe.

Mankind Pharma Ltd. - Share Price

Check the latest share price of Mankind Pharma Ltd. and stay updated with real-time market fluctuations. Our pre-built screening tools allow you to track the stock price, monitor trends, and make informed investment decisions.

Mankind Pharma Ltd. - Balance Sheet

The balance sheet of Mankind Pharma Ltd. provides a snapshot of the company's financial position. Analyze the company's assets, liabilities, and equity to gain insights into its overall financial health. We offer premium features such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis to help you calculate fair value.

Mankind Pharma Ltd. - Annual Report

Access the annual reports of Mankind Pharma Ltd. on our website. These reports offer a comprehensive overview of the company's performance, achievements, and future plans. Gain valuable insights into the company's strategies, growth trajectory, and competitive advantage.

Mankind Pharma Ltd. - Dividend

Stay updated with the company's dividend history and payout ratios. Mankind Pharma Ltd. has a track record of consistently rewarding its shareholders through dividends. Our website provides downloadable resources such as dividend history and financial statements for your analysis.

Mankind Pharma Ltd. - Quarterly Result

Get access to the latest quarterly results of Mankind Pharma Ltd. Track the company's revenue, profit, and other key financial metrics to gauge its performance. Our premium features enable you to analyze these results in conjunction with our comprehensive tools for fair value calculation.

Mankind Pharma Ltd. - Stock Price

Monitor the stock price of Mankind Pharma Ltd. and keep track of its historical performance. Our price charts provide a visual representation of the stock's movement over time. Utilize our pre-built screening tools to identify trends, patterns, and potential investment opportunities.

Mankind Pharma Ltd. - News

Stay updated with the latest news and developments related to Mankind Pharma Ltd. Our website provides curated news articles that cover the company's activities, regulatory updates, product launches, and industry trends. Stay informed and make well-informed investment decisions.

Mankind Pharma Ltd. - Concall Transcripts

Access the conference call transcripts of Mankind Pharma Ltd. These transcripts provide a detailed account of the discussions and presentations made during the company's conference calls. Stay informed about management's outlook, strategic initiatives, and future plans.

Mankind Pharma Ltd. - Investor Presentations

Explore the investor presentations of Mankind Pharma Ltd. These presentations offer valuable insights into the company's operations, growth prospects, and market dynamics. Access downloadable resources on our website to stay updated with the latest investor presentations.

Mankind Pharma Ltd. - Promoters

Learn about the promoters of Mankind Pharma Ltd. and their contribution to the company's success. Understand their vision, leadership style, and strategic direction to assess the stability and long-term potential of the company.

Mankind Pharma Ltd. - Shareholders

Discover the major shareholders of Mankind Pharma Ltd. and their significance in the company's ownership structure. Gain insights into the involvement of institutional investors and public shareholders, which play a crucial role in determining the company's governance and market dynamics.

Remember to visit our website for downloadable resources such as annual reports, concall transcripts, investor presentations, credit ratings, and research reports. Our pre-built screening tools and premium features provide you with the necessary tools to analyze and make informed investment decisions.

Read More
X